ATE446286T1 - Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems - Google Patents

Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems

Info

Publication number: ATE446286T1
Authority: AT; Austria
Prior art keywords: obesity; piperidine; treatment; nervous system; central nervous
Prior art date: 2001-11-26

Application number

AT02786803T

Other languages

English (en)

Inventor

Duane Burnett

Wen-Lian Wu

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-26

Filing date

2002-11-25

Publication date

2009-11-15

2002-11-25 Application filed by Schering Corp filed Critical Schering Corp

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE446286T1 publication Critical patent/ATE446286T1/de

Links

NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
208000008589 Obesity Diseases 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
208000015114 central nervous system disease Diseases 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Nutrition Science (AREA)
Heart & Thoracic Surgery (AREA)
Anesthesiology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT02786803T 2001-11-26 2002-11-25 Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems ATE446286T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33336701P	2001-11-26	2001-11-26
PCT/US2002/037956 WO2003045918A1 (en)	2001-11-26	2002-11-25	Piperidine-based mch antagonists for treatment of obesity and cns disorders

Publications (1)

Publication Number	Publication Date
ATE446286T1 true ATE446286T1 (de)	2009-11-15

Family

ID=23302485

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02786803T ATE446286T1 (de)	2001-11-26	2002-11-25	Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems

Country Status (18)

Country	Link
US (1)	US6664273B2 (de)
EP (1)	EP1448526B1 (de)
JP (2)	JP2005510563A (de)
KR (1)	KR20040058307A (de)
CN (1)	CN1592739A (de)
AR (1)	AR037429A1 (de)
AT (1)	ATE446286T1 (de)
AU (1)	AU2002350269B2 (de)
CA (1)	CA2467857C (de)
DE (1)	DE60234116D1 (de)
ES (1)	ES2333415T3 (de)
HU (1)	HUP0402404A3 (de)
IL (1)	IL161717A0 (de)
MX (1)	MXPA04004956A (de)
PE (1)	PE20030809A1 (de)
TW (1)	TW200301115A (de)
WO (1)	WO2003045918A1 (de)
ZA (1)	ZA200403784B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070135425A1 (en) *	2001-05-04	2007-06-14	Amgen Inc.	Fused heterocyclic compounds
US6809104B2 (en) *	2001-05-04	2004-10-26	Tularik Inc.	Fused heterocyclic compounds
BR0209932A (pt) *	2001-05-22	2004-10-13	Neurogen Corp	Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto
AU2002352878B2 (en)	2001-11-27	2007-11-22	Merck Sharp & Dohme Corp.	2-Aminoquinoline compounds
WO2003060475A2 (en) *	2002-01-10	2003-07-24	Neurogen Corporation	Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
MXPA05004739A (es) *	2002-11-06	2005-08-02	Tularik Inc	Compuestos heterociclicos fusionados.
AU2003284402A1 (en) *	2002-11-15	2004-06-15	Yamanouchi Pharmaceutical Co., Ltd.	Antagonist to melanin-concentrating hormone receptor
AU2004209505B2 (en) *	2003-02-10	2009-07-23	Banyu Pharmaceutical Co., Ltd.	Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
US20040242568A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
GB0310724D0 (en) *	2003-05-09	2003-06-11	Glaxo Group Ltd	Chemical compounds
WO2005005419A1 (en) *	2003-06-30	2005-01-20	Schering Corporation	Mch antagonists for the treatment of obesity
MXPA06001601A (es)	2003-08-13	2006-08-25	Takeda Pharmaceutical	Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
AR045496A1 (es) *	2003-08-29	2005-11-02	Schering Corp	Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
WO2005026148A1 (en)	2003-09-08	2005-03-24	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
EP1667958A2 (de)	2003-10-01	2006-06-14	The Procter & Gamble Company	Antagonisten des melaninkonzentrierenden hormons
CN102079743B (zh) *	2004-03-15	2020-08-25	武田药品工业株式会社	二肽基肽酶抑制剂
EP1729772B8 (de) *	2004-03-24	2017-04-19	Merck Sharp & Dohme Corp.	Heteroaryl-piperidin-glycin-transporterhemmer
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
ES2327763T3 (es) *	2004-07-16	2009-11-03	Schering Corporation	Heterociclilos utilizados como antagonistas del receptor de la hormona concentrada de melanina para el tratamiento de la obesidad y trastornos relacionados.
TW200630337A (en) *	2004-10-14	2006-09-01	Euro Celtique Sa	Piperidinyl compounds and the use thereof
JP2008521821A (ja) *	2004-11-29	2008-06-26	バーテックスファーマシューティカルズインコーポレイテッド	ムスカリン受容体のモジュレーター
JP2008524331A (ja)	2004-12-21	2008-07-10	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤
AU2005317846B2 (en) *	2004-12-21	2011-12-08	Merck Sharp & Dohme Limited	Piperidine and azetidine derivatives as GlyT1 inhibitors
US7786308B2 (en) *	2005-03-28	2010-08-31	Vertex Pharmaceuticals Incorporated	Muscarinic modulators
NZ566799A (en)	2005-09-14	2011-04-29	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors for treating diabetes
WO2007035629A2 (en)	2005-09-16	2007-03-29	Takeda Pharmaceutical Company Limited	Process for the preparation of pyrimidinedione derivatives
WO2007110449A1 (en)	2006-03-29	2007-10-04	Euro-Celtique S.A.	Benzenesulfonamide compounds and their use
TW200812963A (en)	2006-04-13	2008-03-16	Euro Celtique Sa	Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en)	2006-04-13	2007-10-25	Euro-Celtique S.A.	Benzenesulfonamide compounds and their use as blockers of calcium channels
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
PL2073810T3 (pl) *	2006-09-13	2012-01-31	Takeda Pharmaceuticals Co	Zastosowanie 2-6-(3-amino-piperydyn-1-ylo)-3-metylo-2,4-diokso-3,4-dihydro-2H-pirymidyn-1-ylometylo-4-fluoro-benzonitrylu do leczenia cukrzycy, raka, zaburzeń autoimmunizacyjnych i zakażeń HIV
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
WO2008124118A1 (en) *	2007-04-09	2008-10-16	Purdue Pharma L.P.	Benzenesulfonyl compounds and the use therof
US20160331729A9 (en)	2007-04-11	2016-11-17	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
WO2008128126A1 (en)	2007-04-11	2008-10-23	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en)	2007-04-11	2022-02-08	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
WO2009040659A2 (en)	2007-09-28	2009-04-02	Purdue Pharma L.P.	Benzenesulfonamide compounds and the use thereof
US20170280749A1 (en) *	2011-06-09	2017-10-05	Requis Pharmaceuticals	Antihistamines Combined with Dietary Supplements for Improved Health
JP6883817B2 (ja) *	2017-02-10	2021-06-09	株式会社Ｉｈｉエアロスペース	ロケットモータ
KR200487142Y1 (ko)	2017-05-31	2018-08-10	주식회사 에이치에스씨	2차코일이 일체로 형성된 트랜스포머용 가이더
KR102695210B1 (ko)	2018-06-05	2024-08-13	크리네틱스 파마슈티칼스, 인크.	멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도
WO2021091788A1 (en)	2019-11-07	2021-05-14	Crinetics Pharmaceuticals, Inc.	Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
JP7672406B2 (ja) *	2019-12-18	2025-05-07	クリネティックスファーマシューティカルズ，インク．	Ｇｅｍ－二置換ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP7651574B2 (ja)	2019-12-23	2025-03-26	クリネティックスファーマシューティカルズ，インク．	スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
BR112023018816A2 (pt)	2021-03-19	2023-10-31	Crinetics Pharmaceuticals Inc	Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL267843A (de) *	1960-08-03
DE4107857A1 (de)	1991-03-12	1992-09-17	Thomae Gmbh Dr K	Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5908830A (en)	1996-10-31	1999-06-01	Merck & Co., Inc.	Combination therapy for the treatment of diabetes and obesity
US6043246A (en)	1996-12-03	2000-03-28	Banyu Pharmaceutical Co., Ltd.	Urea derivatives
US5953440A (en)	1997-12-02	1999-09-14	Sensar, Inc.	Method of measuring the focus of close-up images of eyes
ATE232200T1 (de)	1998-06-08	2003-02-15	Schering Corp	Neuropeptid y5-rezeptorantagonisten
US7115750B1 (en) *	1999-09-20	2006-10-03	Takeda Pharmaceutical Company Limited	Melanin concentrating hormone antagonist
PT1285651E (pt)	2000-04-28	2010-10-21	Takeda Pharmaceutical	Antagonistas da hormona concentradora da melanina
EP1283199A4 (de)	2000-05-16	2003-12-17	Takeda Chemical Industries Ltd	Antagonisten des melanin-konzentrierenden hormons
CA2443672C (en)	2001-04-12	2011-03-29	Pharmacopeia, Inc.	Aryl and biaryl piperidines used as mch antagonists
GB0124627D0 (en)	2001-10-15	2001-12-05	Smithkline Beecham Plc	Novel compounds

2002
- 2002-11-25 US US10/303,205 patent/US6664273B2/en not_active Expired - Fee Related
- 2002-11-25 IL IL16171702A patent/IL161717A0/xx unknown
- 2002-11-25 CN CNA028235118A patent/CN1592739A/zh active Pending
- 2002-11-25 KR KR10-2004-7007712A patent/KR20040058307A/ko not_active Withdrawn
- 2002-11-25 AT AT02786803T patent/ATE446286T1/de not_active IP Right Cessation
- 2002-11-25 HU HU0402404A patent/HUP0402404A3/hu unknown
- 2002-11-25 JP JP2003547370A patent/JP2005510563A/ja active Pending
- 2002-11-25 ES ES02786803T patent/ES2333415T3/es not_active Expired - Lifetime
- 2002-11-25 WO PCT/US2002/037956 patent/WO2003045918A1/en not_active Ceased
- 2002-11-25 AU AU2002350269A patent/AU2002350269B2/en not_active Ceased
- 2002-11-25 CA CA2467857A patent/CA2467857C/en not_active Expired - Fee Related
- 2002-11-25 MX MXPA04004956A patent/MXPA04004956A/es active IP Right Grant
- 2002-11-25 AR ARP020104529A patent/AR037429A1/es unknown
- 2002-11-25 EP EP02786803A patent/EP1448526B1/de not_active Expired - Lifetime
- 2002-11-25 DE DE60234116T patent/DE60234116D1/de not_active Expired - Lifetime
- 2002-11-26 TW TW091134320A patent/TW200301115A/zh unknown
- 2002-11-26 PE PE2002001134A patent/PE20030809A1/es not_active Application Discontinuation
2004
- 2004-05-17 ZA ZA200403784A patent/ZA200403784B/en unknown
2009
- 2009-08-12 JP JP2009187565A patent/JP2009256390A/ja active Pending

Also Published As

Publication number	Publication date
JP2009256390A (ja)	2009-11-05
JP2005510563A (ja)	2005-04-21
PE20030809A1 (es)	2003-09-22
IL161717A0 (en)	2004-09-27
EP1448526A1 (de)	2004-08-25
ZA200403784B (en)	2005-05-19
HUP0402404A3 (en)	2011-05-30
US6664273B2 (en)	2003-12-16
TW200301115A (en)	2003-07-01
CA2467857A1 (en)	2003-06-05
EP1448526B1 (de)	2009-10-21
CA2467857C (en)	2010-08-24
ES2333415T3 (es)	2010-02-22
US20030199549A1 (en)	2003-10-23
WO2003045918A8 (en)	2005-03-17
AR037429A1 (es)	2004-11-10
KR20040058307A (ko)	2004-07-03
AU2002350269B2 (en)	2006-05-18
MXPA04004956A (es)	2004-08-11
WO2003045918A1 (en)	2003-06-05
AU2002350269A1 (en)	2003-06-10
CN1592739A (zh)	2005-03-09
DE60234116D1 (de)	2009-12-03
HUP0402404A2 (hu)	2005-03-29

Legal Events

Date	Code	Title	Description
2010-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60234116D1 (de)	2009-12-03	Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
ATE302185T1 (de)	2005-09-15	Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
ATE297380T1 (de)	2005-06-15	Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60238149D1 (de)	2010-12-09	Arylsulfonamid-Derivate zur Verwendung als CCR3-Antagonisten bei der Behandlung von inflammatorischen und immunologischen Erkrankungen
ATE447552T1 (de)	2009-11-15	Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE327757T1 (de)	2006-06-15	Verwendung von flibanserin bei der behandung von störungen des sexuellen verlangens
ATE420866T1 (de)	2009-01-15	4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE60319865D1 (de)	2008-04-30	Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE286028T1 (de)	2005-01-15	Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE318821T1 (de)	2006-03-15	Pyranoindazole und ihre verwendung in der glaukombehandlung
DE60223715D1 (de)	2008-01-03	Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten
ATE362473T1 (de)	2007-06-15	1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten
DE60223694D1 (de)	2008-01-03	Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
ATE357440T1 (de)	2007-04-15	Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
NO20043085L (no)	2004-07-13	Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
DE60022867D1 (de)	2006-02-09	1-Arenesulfonyl-2-Aryl-Pyrrolidin und Piperidin Derivative zur Behandlung von CNS-Erkrankungen
ATE269078T1 (de)	2004-07-15	Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
NO20031903L (no)	2003-06-25	Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser
ATE303379T1 (de)	2005-09-15	4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE478052T1 (de)	2010-09-15	1,3,4-substituierte pyrazole als 5-ht rezeptor- antagonisten zur behandlung von psychosen und neurologischen störungen
ATE514431T1 (de)	2011-07-15	Allergie-vakzine-zusammensetzung, herstellungsverfahren dafür und ihre verwendung bei der behandlung von allergien
DE60221275D1 (de)	2007-08-30	Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
DE60219687D1 (de)	2007-05-31	Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
DE69915113D1 (de)	2004-04-01	5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
EE200300527A (et)	2004-02-16	4-(fenüülpiperidiin-4-ülideenmetüül)bensamiidi derivaadid ja nende kasutamine valu, ärevuse või seedetrakti häirete raviks